Epigenomics AG

EANS-News: Epigenomics AG
Epigenomics signs licensing agreement with BioChain for Septin9 in China

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Licensing Agreements/New Products/Molecular Diagnostics

Berlin, Germany, Seattle, WA, and San Francisco, CA, U.S.A., Beijing, China
(euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), the
German-American cancer molecular diagnostics company, and BioChain, a leading
Clinical Diagnostics company in cancer and genetic tests, today announced that
BioChain has licensed Epigenomics' methylated Septin9 marker for the blood based
detection of colorectal cancer (CRC). BioChain, will offer a Septin9 assay as a
service to customers through its' Beijing based Chinese independent reference

Grace Tian, Chief Executive Officer of BioChain Institute, Inc., U.S.A., noted:
"Through this agreement we will immediately initiate efforts in China to
validate and deploy the methylated Septin9 assay allowing the establishment of
new standards for access and convenience in our home market. We see this effort
as a first step in developing a relationship with Epigenomics to bring early
stage cancer detection to the market."

Additionally, Dr. Thomas Taapken, Chief Financial Officer and acting Chief
Executive Officer of Epigenomics, commented: "We are pleased that BioChain has
decided to collaborate with us in making a methylated Septin9 assay available in
mainland China. This allows more convenient alternatives for CRC screening to
become available in this emerging market, where prevalence of CRC in the
population is on the raise and growing awareness is creating a need for early

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR 
Epigenomics AG 
Tel +49 (0) 30 24345 368 

About BioChain

BioChain ({www.biochain.com}[HYPERLINK: http://www.biochain.com],
www.biochainbj.com) is a manufacturer of Life Sciences tools and the pioneer of
molecular genetics diagnostics in the US and China. It is also the owner and
operator of an independent reference laboratory, equivalent of a CLIA lab, in
China - Beijing BioChain Medical Laboratory (BBML). BBML is unique in that it
focuses on the application of molecular diagnostics technologies and products.
BBML is located in the economic development zone of Beijing, China. Through
BBML, BioChain is committed to the application of the cutting edge "omics"
technologies in the areas of reproductive health and cancer diagnosis.

BBML offers comprehensive services to its customers in China with a list of
cellular and molecular test menus based on diverse technologies appropriate to
each stage and type of disease. Technology platforms employed by BioChain
include karyotyping analysis of cytogenetics, fluorescent in-situ hybridization
(FISH), array comparative genomic hybridization (aCGH), quantitative PCR (qPCR),
Sanger sequencing, next generation sequencing (NGS), multiplex
ligation-dependent probe amplification (MLPA), and genetic linkage analysis.
BioChain has a strong bioinformatics team and established the first Chromosomal
Health Database for the Chinese population (www.szjkzd.org:8080/app/auth).

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing
and commercializing a pipeline of proprietary products for cancer. The Company's
products enable doctors to diagnose cancer earlier and more accurately, leading
to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is
a blood-based test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe
and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise. 

The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States or Canada.
The analytical and clinical performance characteristics of any Epigenomics
product based on this technology which may be sold at some future time in the
U.S. have not been established.

Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386

end of announcement                               euro adhoc 

company:     Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: